Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Islatravir (MK-8591) in Subjects With Severe Renal Impairment

Trial Profile

An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Islatravir (MK-8591) in Subjects With Severe Renal Impairment

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Islatravir (Primary)
  • Indications HIV infections; HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

  • 08 Nov 2022 Results assessing he impact of renal impairment on the pharmacokinetics of islatravir in individuals with severe renal insufficiency, published in the Antimicrobial Agents and Chemotherapy.
  • 21 Jul 2021 Results assessing safety and tolerability in individuals with severe renal insufficiency and healthy matched control presented at the 11th International AIDS Society Conference on HIV Science
  • 28 Oct 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top